Connect with us

Hi, what are you looking for?


Sosei Heptares Announces Antitrust Clearance of License Agreement With Neurocrine Biosciences

TOKYO, Japan and CAMBRIDGE, United Kingdom, Dec. 23, 2021 (GLOBE NEWSWIRE) — Sosei Group Corporation (“Sosei Heptares”; TSE: 4565) today announces that in connection with the Collaboration and License Agreement (“License Agreement”) with Neurocrine Biosciences, Inc. (“Neurocrine Biosciences”) announced 22 November 2021, the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (“HSR Act”) expired on 22 December 2021. As such, the License Agreement became effective on 22 December 2021. With completion of the applicable waiting period under the HSR Act, under the terms of the License Agreement Neurocrine Biosciences has agreed to pay Sosei Heptares an upfront payment of US$100 million, with the amount to be recognized as revenue in the fourth quarter of the financial year ending December 31, 2021.

About Sosei Heptares
We are an international biopharmaceutical group focused on the discovery and early development of new medicines originating from our proprietary GPCR-targeted StaR® technology and structure-based drug design platform capabilities. We are …

Full story available on

Source Here:

Click to comment

Leave a Reply

Your email address will not be published.

You May Also Like


Arbutus’ Lead Compound AB-729 Continues to be Safe and Effective at Reducing HBsAg in Patients with Chronic Hepatitis B HBsAg remains suppressed up to...


The Fourth Single ‘Eyy Bidda Idhi Naa Adda’ From Allu Arjun’s Pushpa Is Out… The Fourth Single ‘Eyy Bidda Idhi Naa Adda’ From Allu...


Kyle Rittenhouse testifies about Gaige Grosskreutz holding a gun toward him during his trial at the Kenosha County Courthouse on November 10, 2021 in...


PHILADELPHIA, Nov. 09, 2021 (GLOBE NEWSWIRE) — AnPac Bio-Medical Science Co., Ltd. (NASDAQ:ANPC, the “Company”)), a biotechnology company with operations in China and the...